Trial registration: A great idea switches from ignored to irresistible

JAMA

Volumn 292, Issue 11, 2004, Pages 1359-1362

  Rennie, Drummond ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

CLINICAL TRIAL; DRUG INDUSTRY; DRUG MANUFACTURE; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL ETHICS; MEDICAL LITERATURE; MEDICAL SOCIETY; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; REGISTRATION; RISK BENEFIT ANALYSIS; BIOMEDICAL AND BEHAVIORAL RESEARCH; POLITICS; PUBLISHING; REGISTER; STANDARD; UNITED STATES;

BIOMEDICAL AND BEHAVIORAL RESEARCH;

AMERICAN MEDICAL ASSOCIATION; CLINICAL TRIALS; DRUG INDUSTRY; EDITORIAL POLICIES; PERIODICALS; POLITICS; PUBLISHING; REGISTRIES; UNITED STATES;

EID: 4544370265     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.11.1359     Document Type: Note

References (43)

1. Dickersin K, Rennie D. Registering clinical trials. JAMA. 2003;290:516-523.
2. Manheimer E, Anderson D. Survey of public information about ongoing clinical trials funded by industry: evaluation of completeness and accessibility. BMJ. 2002;325:528-531.
3. Furberg CD. Effect of antiarrhythmic drugs on mortality after myocardial infarction. Am J Cardiol. 1983;52:32C-36C.
4. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA. 1993;270:1589-1595.
5. Hirsch L. Randomized clinical trials: what gets published, and when? CMAJ. 2004;170:477-480.
6. Pharmaceutical Research and Manufacturers of America. PhRMA principles on conduct of clinical trials and communication of trial results (effective October 1, 2002]. Available at: http://www.phrma.org/publications/quickfacts/20. 06.2002.428.cfm. Accessed July 28, 2004.
7. Pharmaceutical Research and Manufacturers of America. Updated principles for conduct of clinical trials and communication of clinical trial results [press release]. June 30, 2004. Available at: http://www.phrma.org/mediaroom/ press/releases/30.06.2004.427.cfm. Accessed July 28, 2004.
8. People of the State of New York v GlaxoSmithKline. Filed June 2, 2004.
9. Durman P, Rushe D. Glaxo faces criminal action in Britain over "suicide" pills. Times of London. June 6, 2004. Available at: http://business.timesonline.co.uk/article/0,8209-1135320,00.html. Accessed August 9, 2004.
10. Kondro W. Drug company experts advised staff to withhold data about SSRI use in children. CMAJ. 2004;170:783.
11. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet. 2004;363:1341-1345.
12. Interim Report of the Committee on Safety of Medicines' Expert Working Group on Selective Serotonin Reuptake Inhibitors. London, England: Medicine and Healthcare Products Regulatory Agency; 2003. Available at: http://www.mca.gov. uk/ourwork/monitorsafequalmed/safetymessages/ssriewginterimreportfinal.pdf. Accessed August 9, 2004.
13. Peston R, Pfeifer S. Garnier comes out fighting: GSK's chief executive tells Sylvia Pfeifer and Robert Peston why the lawsuit filed by the New York attorney general has made him very angry. Sunday Telegraph. June 6, 2004. Available at: http://www.business.telegraph.co.uk/money/main.jhtml?xml=/money/ 2004/06/06/ccglax06.xml. Accessed June 15, 2004.
14. Is GSK guilty of fraud? Lancet. 2004;363:1919,
15. Meier B. Spitzer asks drug maker for off-label use material. New York Times. August 4, 2004. Available at: http://www.nytimes.com/2004/08/04/business/ 04drug.html. Accessed August 18, 2004.
16. American Medical Association Council on Scientific Affairs. Influence of Funding Source on Outcome, Validity, and Reliability of Pharmaceutical Research. Available at: http://www.ama-assn.org/ama/pub/article/2036-8608.html. Accessed August 9, 2004.
17. American Medical Association. AMA recommends that DHHS establish a registry for all US clinical trials [press release]. June 15, 2004. Available at: http://www.ama-assn.org/ama/pub/article/1616-8651.html. Accessed August 8, 2004.
18. Meier B. AMA adds its voice to call for disclosure on drug trials. New York Times. June 16, 2004:C-1.
19. American Medical Association House of Delegates. Access to FDA data regarding the safety and efficacy of medications. May 5, 2004. Resolution 529;10.
20. GlaxoSmithKline. GlaxoSmithKline announces major advance in on-line access to clinical trial information [press release]. June 18, 2004. Available at: http://www.gsk.com/media/archive.htm. Accessed August 5, 2004.
21. Gibson L. GlaxoSmithKline to publish clinical trials after US lawsuit. BMJ. 2004;328:1513.
22. Kusmer K. Lilly to disclose drug trial results. Associated Press. August 3, 2004, http://www.abcnews.go.com/wire/Business/ap20040803_1680.html. Accessed August 18, 2004.
23. Meier B. Merck backs US database to track drug trials. New York Times. June 18, 2004:C-1.
24. Abboud L. Lilly plans broad access to results of drug trials. Wall Street Journal. August 3, 2004.
25. Eli Lilly and Co. Lilly to disclose results of all clinical trials for marketed products via a publicly available registry [press release]. August 3, 2004. Available at: http://newsroom.lilly.com/news/corporate/2004_08- 03_clinical_trials_registry.html. Accessed August 3, 2004.
26. Holmer AF. Choosing prescription drugs-one firm's bold step helps doctors, patients avoid errors: opposing view. USA Today. August 10, 2004:A-10.
27. Rennie D. Fair conduct and fair reporting of clinical trials. JAMA. 1999;282:1766-1768.
28. Sykes R. Being a modern pharmaceutical company: involves making information available on clinical trial programmes. BMJ. 1998;317:1172.
29. Herxheimer A. Open access to industry's clinically relevant data. BMJ. 2004;329:64-65.
30. CMR International. Pharmaceutical Industry Clinical Trials Database. Available at: https://www.cmrinteract.com/clintrial/. Accessed August 3, 2004.
31. Groppe M. Lawmaker seeks clinical trial data: antidepressant makers, including Eli Lilly, asked to submit results of tests of children. Indianapolis Star. August 5, 2004. Available at: http://www.indystar.com/articles/0/167890- 1220-P.html. Accessed August 4, 2004.
32. Mathews AW. FDA revisits issue of antidepressants for youths - new analysis may pressure agency to set limit on use because of suicide risk. Wall Street Journal. August 5, 2004:A-1.
33. Wadman M. Tough talker quits Congress for bioindustry. Nature. 2004;430:495.
34. Garland EJ. Facing the evidence: antidepressant treatment in children and adolescents. CMAJ. 2004;170:489-491.
35. Wessely S, Kerwin R. Suicide risk and the SSRIs. JAMA. 2004;292:379-381.
36. US Food and Drug Administration. FDA Upcoming Meetings Announcement: joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Pediatric Advisory Committee - September 13-14, 2004. Available at: http: //www.fda.gov/oc/advisory/accalendar/2004/cder12544dd09131404.html. Accessed August 8, 2004.
37. Treatment for Adolescents With Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. 2004;292:807-820.
38. Glass RM. Treatment of adolescents with ma)or depression: contributions of a major trial. JAMA. 2004;292:861-863.
39. Pear R. In a shift, Bush moves to block medical suits. New York Times. July 25, 2004. Available at: http://www.nytimes.com/2004/07/25/politics/25DRUG. html. Accessed August 18, 2004.
40. Matthews AW, Burton TM. After Medtronic lobbying push, the FDA had change of heart. Wall Street Journal. 2004:A-1.
41. Chan A-W, Hróbjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004;291:2457-2465.
42. Clinical Trial Registration: a statement from the International Committee of Medical Journal Editors. JAMA. 2004;292:1363.
43. Settlement sets new standard for release of drug information [press release]. New York, NY: Office of New York State Attorney General Eliot Spitzer; August 26, 2004, Available at: http://www.oag.state.ny.us/press/2004/aug/ aug26a_04.html. Accessed August 27, 2004.